News articles about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Moleculin Biotech earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6750854852111 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Moleculin Biotech (MBRX) traded down $0.05 during trading on Tuesday, reaching $1.82. The company’s stock had a trading volume of 98,571 shares, compared to its average volume of 170,933. The stock has a market capitalization of $38.35 and a price-to-earnings ratio of -3.87. Moleculin Biotech has a fifty-two week low of $0.71 and a fifty-two week high of $3.75.
Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.14) EPS for the quarter. sell-side analysts forecast that Moleculin Biotech will post -0.47 earnings per share for the current fiscal year.
About Moleculin Biotech
Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.